See more : Aon plc (AON) Income Statement Analysis – Financial Results
Complete financial analysis of GRI Bio, Inc. (GRI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRI Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DuZhe Publish&Media Co.,Ltd (603999.SS) Income Statement Analysis – Financial Results
- PensionBee Group plc (PBEE.L) Income Statement Analysis – Financial Results
- Kurabo Industries Ltd. (3106.T) Income Statement Analysis – Financial Results
- Electricity Generating Public Company Limited (EGCO.BK) Income Statement Analysis – Financial Results
- Polytronics Technology Corp. (6224.TW) Income Statement Analysis – Financial Results
GRI Bio, Inc. (GRI)
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 21.77M | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Cost of Revenue | 57.00K | 206.00K | 73.00K | 0.00 | 735.00 | 612.00 |
| Gross Profit | 21.71M | -206.00K | -73.00K | 100.00K | -735.00 | -612.00 |
| Gross Profit Ratio | 99.74% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.23M | 242.00K | 249.00K | 3.71M | 1.88M | 3.51M |
| General & Administrative | 1.49M | 2.00M | 813.00K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.10M | 2.00M | 813.00K | 1.11M | 1.27M | 800.08K |
| Other Expenses | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.33M | 2.24M | 1.06M | 4.81M | 3.15M | 4.31M |
| Cost & Expenses | 11.39M | 2.24M | 1.06M | 4.89M | 3.15M | 4.31M |
| Interest Income | 0.00 | 26.00K | 0.00 | 0.00 | 0.00 | 1.06K |
| Interest Expense | 2.08M | 653.00K | 547.00K | 34.00K | 197.03K | 0.00 |
| Depreciation & Amortization | 57.00K | 50.00K | 73.00K | 75.00K | 735.00 | 612.00 |
| EBITDA | -10.90M | -2.51M | -9.21M | -4.71M | -3.27M | -4.31M |
| EBITDA Ratio | -50.07% | 0.00% | 0.00% | -4,713.00% | 0.00% | 0.00% |
| Operating Income | -11.39M | -2.24M | -1.06M | -4.79M | -3.15M | -4.31M |
| Operating Income Ratio | -52.31% | 0.00% | 0.00% | -4,788.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -978.00K | -8.24M | -34.00K | -310.07K | 1.06K |
| Income Before Tax | -13.04M | -3.22M | -1.56M | -4.82M | -3.46M | -4.31M |
| Income Before Tax Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.77M | 325.00K | -50.00K | -131.30K | 5.00 | -2.00 |
| Net Income | -13.04M | -3.54M | -1.51M | -4.82M | -3.46M | -4.31M |
| Net Income Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| EPS | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| EPS Diluted | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| Weighted Avg Shares Out | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
| Weighted Avg Shares Out (Dil) | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Live webcast on Thursday, December 12 th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer...
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
Workshop, poster and oral presentation of data given as part of the 8 th Annual Antifibrotic Drug Development (AFDD) Summit
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio Announces Exercise of Warrants
LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis
UK residential rent rises are slowing but Grainger says demand remains strong
Grainger Plc (LSE:GRI) reported slower rental growth for recent months and said it expects further slowing in the coming year. The FTSE 250-listed private landlord, which owns around 12,000 homes, said rental growth was 6.3% in the year ending 30 September 2024...
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
Live video webcast on Wednesday, October 2 nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline...
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
Source: https://incomestatements.info
Category: Stock Reports